Granules India Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Granules India reported strong full-year results with consolidated revenue growing 19.7% to Rs 53,656 million and profit rising 18.6% to Rs 5,950 million. Standalone revenue was Rs 30,302 million with profit of Rs 401 million, up 25.5% year-on-year. The company completed acquisition of Senn Chemicals AG (Switzerland) in April 2025 and Granules Pharmaceuticals GmbH (Germany) in November 2025, expanding its global footprint. The Gagillapur facility received a USFDA warning letter in February 2025 following an inspection, leading to temporary production pause and increased consultancy expenses. The Board recommended a dividend of Rs 1.75 per share. Auditors issued an unmodified opinion with no going concern issues.
Revenue growth nearly hit 20% on consolidated basis, with PAT growth exceeding 25% on standalone basis, indicating strong operational performance. The expansion into European markets through acquisitions should support future growth, though investors should monitor the resolution of USFDA concerns at Gagillapur facility.